Bioxyne Limited’s subsidiary, Breathe Life Sciences, has obtained the Good Manufacturing Practice (GMP) licence for medical cannabis production, encompassing Psilocybin and MDMA. This marks a significant milestone as the first GMP certification for these substances in Australia. The company aims to supply these products to authorised prescribers and for clinical trials, focusing on treating mental health disorders whilst actively seeking partnerships.
Read the full story here
Written by: Kate B.
Published on February 6, 2024 at 07:30PM
Source: Australian Manufacturing (opens in new tab)